{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2021"],"data_sharing_plan":["IPD Sharing (as of February 2022): No"],"condition":["Unresectable Metastatic Colorectal Cancer","Colorectal Neoplasms"],"disease":["Unresectable Metastatic Colorectal Cancer","Colorectal Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2385614"],"location":["Belgium","United States"],"study_start_month":["11"],"keyword":["Pembrolizumab"],"repository":["ECRIN MDR"],"study_status":["Recruiting"],"additional_accession":[]},"is_claimable":false,"name":"Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer","description":"The purpose of the CYAD-101-002 study is to assess the safety and clinical activity of CYAD-101 in patients with unresectable metastatic colorectal cancer administered concurrently with FOLFOX chemotherapy, followed by pembrolizumab treatment.","dates":{"creation":"2021-11-15"},"accession":"2385614","cross_references":{"ClinicalTrials___gov":["NCT04991948"]}}